Trials / Terminated
TerminatedNCT00154427
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in Africa, Asia, Europe, South America and the United States of America (USA). The trial is planned to investigate the safety and efficacy of NovoSeven® in the management of post-operative bleeding in patients following cardiac surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | activated recombinant human factor VII |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2005-09-12
- Last updated
- 2017-01-12
Locations
63 sites across 14 countries: United States, Argentina, Brazil, Denmark, France, Germany, India, Italy, Malaysia, Singapore, South Africa, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00154427. Inclusion in this directory is not an endorsement.